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Hyperventilation-induced heart 
rate response as a potential marker 
for cardiovascular disease
Selwynne M. Hawkins1, Dominik p. Guensch2,3, Matthias G. friedrich4,5,6, Giulia Vinco4,7, 
Gobinath nadeshalingham8, Michel White8, francois-pierre Mongeon8, elizabeth Hillier1, 
tiago teixeira8,10, Jacqueline A. flewitt9, Balthasar eberle2 & Kady fischer  2,3*
An increase of heart rate to physical or mental stress reflects the ability of the autonomous nervous 
system and the heart to respond adequately. Hyperventilation is a user-controlled breathing maneuver 
that has a significant impact on coronary function and hemodynamics. Thus, we aimed to investigate if 
the heart rate response to hyperventilation (HRRHV) can provide clinically useful information. A pooled 
analysis of the HRRHV after 60 s of hyperventilation was conducted in 282 participants including healthy 
controls; patients with heart failure (Hf); coronary artery disease (cAD); a combination of both; or 
patients suspected of CAD but with a normal angiogram. Hyperventilation significantly increased heart 
rate in all groups, although healthy controls aged 55 years and older (15 ± 9 bpm) had a larger HRRHV 
than each of the disease groups (HF: 6 ± 6, CAD: 8 ± 8, CAD+/Hf+: 6 ± 4, and CAD−/Hf−: 8 ± 6 bpm, 
p < 0.001). No significant differences were found between disease groups. The HRRHV may serve as an 
easily measurable additional marker of cardiovascular health. future studies should test its diagnostic 
potential as a simple, inexpensive pre-screening test to improve patient selection for other diagnostic 
exams.
Cardiovascular disease affects nearly one third of people over the age of 651 in developed countries and places 
considerable financial strain on health care systems2,3. As a result, research focused on predictive metrics of cardi-
ovascular disease is paramount4. Presently, several diagnostic tests are used—including stress tests and coronary 
angiograms—to verify or exclude the presence of cardiovascular disease. However, these approaches have many 
limitations, including higher costs, intricate diagnostic equipment, exposure to radiation, invasive procedures, 
or injections of pharmacological agents. These factors restrict their clinical utility. Tests like 12-lead ECG and 
physical exams are more easily accessible, but often provide less information than imaging modalities5. The addi-
tion of a simple pre-screening test, performed without supplemental imaging techniques, could supplement the 
information gained through existing screening tests and reduce the number of costly advanced diagnostic tests.
Heart rate (HR), an accessible, quantifiable measure, has long been investigated as a predictor of cardiovascu-
lar disease and mortality6,7. A higher resting HR has been shown to be correlated with higher risk of cardiovascu-
lar disease and death in the general population and several patient groups, including heart failure with preserved 
ejection fraction (HFpEF)8 and coronary heart disease9,10. Another similar assessment associated with cardio-
vascular disease is HR variability, measured through stationary or ambulatory recordings11–13. Such parameters 
however may not consistently be abnormal at rest. Therefore, inducible HR changes as a response to physiological 
stress could provide useful incremental information. The response of the heart rate to stress, commonly exercise 
or pharmacological injection, has been shown to hold prognostic and diagnostic power. An inadequate heart rate 
response to increased activity, chronotropic incompetence, is especially prevalent in patients with heart failure 
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(HF)14. The heart rate response to exercise has been shown to distinguish HF patients from age-matched controls 
and those with hypertension15, while a large outcome based analysis of the general population demonstrated that 
the magnitude of the heart rate response increase following exercise was a predictor of sudden cardiac death16. 
The heart rate response to adenosine has also been associated with advanced myocardial imaging results as one 
of the strongest negative predictors of reduced coronary flow reserve in women with non-obstructive coronary 
artery disease17. Additionally, a diminished heart rate response to adenosine infusion was an incremental prog-
nostic marker for cardiovascular outcomes beyond traditional clinical and imaging risk factors, especially for 
women18. A heart rate response can also be induced through voluntary hyperventilation without the need for 
exercise of an injected agent. In nineteen controls we previously reported that while adenosine increased HR by 
18 ± 14 bpm, an increase of 25 ± 14 bpm was also observed with hyperventilation19, although it is so far unknown 
if this is related to cardiovascular health.
Recently, cardiovascular magnetic resonance (CMR) studies by our groups and collaborators have used hyper-
ventilation as a tool to investigate myocardial oxygenation and heart disease19–21. CMR, while considered the 
gold standard modality for many cardiac function and tissue parameters, is not suitable as an initial diagnostic or 
screening test because of the associated cost. On the other hand, the response of the heart rate to hyperventilation 
(HRRHV) would not require any equipment other than a device to measure heart rate. To investigate whether the 
HRRHV may have potential as a preliminary indicator of cardiovascular health, we undertook a retrospective 
pooled analysis to investigate if differences in heart rate responses differ between controls and patient groups 
with CAD and HF.
Results
Study population. The baseline characteristics of healthy subjects and patients are summarized in Table 1. 
In total, 161 healthy controls, of which 30 participants were aged 55 years and older, and 121 patients were 
included. Of the patients, n = 54 were classified as CAD + , n = 34 as HF + , with n = 18 as having both CAD and 
HF (CAD + /HF + ). The remaining n = 15 were classified into the CAD−/HF− group as patients who presented 
with CAD symptoms but had no heart failure symptoms or significant coronary stenosis as evaluated via angi-
ography. Large proportions of our patients were taking beta blockers, calcium channel antagonists, angiotensin 
converting enzyme (ACE) inhibitors, angiotensin-2 receptor blockers (ARB), and statins. In two studies, partici-
pants however were instructed to refrain from taking beta blockers on the morning of their CMR scan; in all other 
studies, participants continued medication normally, as defined by local guidelines.
All Controls (n = 161) Controls 55 + (n = 30) CAD (n = 54) HF (n = 34) CAD+/ HF + (n = 18) CAD−/HF− (n = 15)
Participant Characteristics
Age (years) 41.0 ± 13.9 59.8 ± 4.6 63.0 ± 10.2 61.5 ± 10.8 63.4 ± 9.1 61.6 ± 9.3
Gender (female) 71 (44%) 11 (37%) 6 (11%)* 15 (45%) 1 (6%) 5 (33%)
BMI (kg/m2) 24.7 ± 3.2 25.9 ± 3.0 27.9 ± 4.3 30.3 ± 6.2* 28.0 ± 3.6 26.7 ± 3.7
Systolic blood pressure 
(mmHg) 124.8 ± 14.9 132.3 ± 15.2 135.4 ± 15.8 124.2 ± 20.0 126.1 ± 20.2 127.7 ± 18.2
Diastolic blood pressure 
(mmHg) 77.4 ± 11.3 84.3 ± 12.5 78.7 ± 12.3 74.8 ± 9.5* 75.9 ± 11.1* 72.2 ± 9.0*
Resting heart rate (bpm) 62.7 ± 8.6 60.8 ± 7.5 64.4 ± 11.1 64.3 ± 11.1 62.1 ± 11.9 59.2 ± 6.8
Ejection fraction (%) 63.6 ± 6.3 64.8 ± 6.3 63.1 ± 8.5† 53.3 ± 13.3* 54.9 ± 11.8* 69.0 ± 8.6
Cardiac index (L/min/m2) 3.1 ± 0.7 2.9 ± 0.7 3.0 ± 0.9† 2.6 ± 0.6 2.8 ± 1.1 2.7 ± 0.4
Comorbidities
Diabetes — — 15 (28%) 9 (27%) 8 (44%) 0 (0%)
Smoking — — 6 (11%) 6 (18%) 5 (28%) 1 (7%)
History of coronary artery 
reperfusion — — 15 (28%) 0 (0%) 15 (83%) 0 (0%)
Sleep apnea — — 5 (9%) 2 (6%) 2 (11%) 2 (13%)
Dyslipidemia — — 33 (61%) 14 (42%) 11 (61%) 10 (71%)
Medication
Calcium channel antagonists — — 12 (22%) 3 (9%) 1 (6%) 0 (0%)
ACE inhibitors — — 13 (24%) 8 (24%) 6 (33%) 0 (0%)
Statins — — 42 (78%) 13 (39%) 15 (83%) 10 (67%)
Beta blockers — — 36 (66%) 22 (66%) 13 (72%) 8 (53%)
  Taken on exam day — — 12 (22%) 14 (42%) 12 (67%) 0 (0%)
  Halted on exam day — — 24 (44%) 8 (24%) 1 (5%) 8 (53%)
Table 1. Participant Demographics Continuous variables are reported as mean ± SD. Categorical variables 
are reported as the number of occurrences in each group (n(%)). Furthermore, data for healthy controls are 
shown for the entire group, as well as for the sub-group of controls aged 55 years and older. *p < 0.05 indicates a 
significant differences between controls aged ≥ 55 years and each diseased group. †Ejection fraction and cardiac 
index were only available for 16/54 CAD patients. ACE: angiotensin-converting enzyme, BMI: body mass index.
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Hyperventilation response. All groups had a significant increase in heart rate between rest and 
post-hyperventilation (Table 2). The entire healthy control group composed of participants of all ages had an 
HRRHV of 25 ± 14 bpm, while the ≥55 years control sub-group yielded an HRRHV of 15 ± 9, and this was signifi-
cantly greater than any HRRHV observed in the patient groups (Fig. 1). Between the patient groups, no significant 
differences were found. When combining all patients (n = 121), the HRRHV was 7 ± 7 bpm.
impact of possible confounders. Age had an inverse relationship with heart rate change in healthy con-
trols, but not in patients with cardiovascular disease. As shown in Fig. 2A, the difference between groups was 
smaller with increasing age. Similarly, cardiac index had a positive relationship with HRRHV in healthy controls of 
all ages, but not in the sub-group aged 55 years and older (Supplemental Fig. 1), while resting HR was not a sig-
nificant factor for any group (Fig. 2B). Additionally, diabetes, obstructive sleep apnea and dyslipidemia were not 
associated with HRRHV in the individual patient groups (Supplemental Fig. 1). The majority of the cardiovascular 
patient populations were taking beta blockers when recruited for their respective study (Table 1). A separation of 
the participants into three groups according to beta blocker status did not show a significant difference between 
participants taking beta blockers and those who did not (p = 0.647, Fig. 3).
Reproducibility. Reproducibility of HRRHV was evaluated with data from 20 healthy controls who repeated 
the breathing maneuver twice in accordance with the protocol from their primary study (Fig. 4). The absolute 
intraclass correlation coefficient (ICC) was calculated to be 0.900 (p < 0.001), indicating good reliability, and the 
Lin concordance coefficient was calculated as 0.987, indicating good reproducibility.
Preliminary diagnostic cut-offs. As no difference in HRRHV was observed between patient groups, all 
cardiovascular patients were combined into a single group for a preliminary assessment of potential cut-offs 
(Supplemental Fig. 2). From these combined groups n = 54 controls and n = 54 patients were pseudo-randomly 
selected during the age-stratification process for inclusion into the ROC analysis (average age for controls: 54 ± 8; 
average age for combined patient group: 55 ± 8). With the age-stratified control group, a HRRHV cut-off of 8.5 
All Controls Controls 55 + CAD HF CAD+/HF+ CAD−/HF−
Resting HR (bpm) 62.7 ± 8.6 61.2 ± 7.2 64.4 ± 11.1 64.3 ± 10.9 62.1 ± 11.9 59.2 ± 6.8
Post-Hyperventilation HR (bpm) 87.4 ± 15.8 76.2 ± 10.4 72.1 ± 12.1 70.0 ± 11.3 68.1 ± 10.8 67.3 ± 8.0
HRRHV (bpm) 24.5 ± 13.8 15.0 ± 8.8 7.6 ± 7.5 5.7 ± 6.4 6.0 ± 4.4 8.2 ± 6.3
p-value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Table 2. Baseline Heart Rate and Heart Rate Response to Hyperventilation (HRRHV). Mean ± SD resting heart 
rate (HR), post-hyperventilation HR and heart rate response (HRRHV). A paired t-test between resting and 
post-hyperventilation HR indicated a significant difference between baseline and post hyperventilation in each 
group.
Figure 1. Heart Rate Response to Hyperventilation. Group medians with the interquartile range are depicted. 
All cardiovascular patient groups had a significantly attenuated HRRHV in comparison to the response of the 
control sub-group 55 years and older (*p < 0.05).
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bpm resulted in a positive predictive value of 89 (78–95)% and a negative predictive value of 91 (80–96)% with an 
HRRHV of 15.5 bpm for distinguishing from cardiovascular patients (Table 3).
Discussion
Our pooled analysis of 9 studies revealed that 60 seconds of hyperventilation consistently induced a marked 
increase of heart rate in healthy controls and in patients with cardiovascular disease. However, the heart rate 
response to hyperventilation (HRRHV) was significantly diminished in cardiovascular patients (HRRHV = 7 ± 7 
for all patients), when compared to controls older than 55years (HRRHV = 15 ± 9). No differences in HRRHV were 
observed between cardiac disease groups.
Although not fully understood, these hyperventilation-induced HR changes are influenced by the interplay 
between several physiological control systems, specifically the autonomic nervous system. CAD patients have 
been observed to have impaired vagal function12, likely contributing to the attenuated HRRHV seen in the CAD 
group. In our study, an attenuation of HRRHV was also observed in HF patients. In HF, the underlying pathophys-
iology is strongly associated with decreased parasympathetic and increased sympathetic activity11,22, which could 
be contributing to the blunted heart rate response seen in the HF population. Decreased autonomic function, as 
seen in cardiovascular disease, also occurs with age23. Interestingly, the same attenuated HRRHV was observed 
in the CAD−/HF− group, patients who presented with cardiac symptoms but no signs of heart failure or angi-
ographically validated obstructive stenoses. However, despite the absence of HF or obstructive CAD, these are 
not healthy patients, as they can have an elevated risk of major adverse cardiac events and lower quality of life, 
especially if stress tests are abnormal. As shown in our analysis, HRRHV in this CAD−/HF− group is in line with 
the classical heart disease groups of CAD and HF, and not healthy controls.
Resting HR has been shown to hold its own prognostic value for cardiovascular patients24,25. A higher resting 
HR could act as a confounder to the HRRHV. Specifically, HF patients often have a higher resting HR as a com-
pensatory measure to counteract a decreased stroke volume in order to maintain cardiac output. In our study 
Figure 2. Impact of Age and Resting HR on HRRHV. (A) Heart Rate Response to Hyperventilation (HRRHV) as 
a function of age for healthy controls and each of the patient groups. (B) HRRHV as a function of resting HR for 
healthy controls (Solid green: all controls, dashed green: sub-group of controls 55 years and older) and each of 
the disease groups. Solid lines indicate linear fit, and dashed lines indicate 95% confidence bounds on the fit.
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population, there was not a significant difference in resting heart rate between healthy controls and any patient 
group. This non-relationship was also observed in a large meta-analysis of controls for multiple methods of stress 
testing, including pharmacological stimuli and dynamic and isometric exercise26. Borlaug et al. similarly showed 
that patients with HFpEF did not have a different resting HR than age-matched hypertensive patients and con-
trols, yet there was a significant difference in the exercise induced heart rate response, even with adjustment for 
beta blocker use15. Furthermore, a separate study showed the severity of HF was associated with a worsening 
exercise-induced heart rate response but neither the severity of HF or the heart rate response were associated with 
the resting HR27. In that study, both, resting HR and the heart rate response were associated with poor outcome 
despite a lack of a relationship between each other. In our analysis, the resting HR was not correlated with the 
hyperventilation-induced HR response in any subgroup. As there are small sample sizes for the individual pathol-
ogies in our study, this relationship should be further assessed with larger groups.
Figure 3. Impact of Beta Blocker Intake on the HRRHV. Box plot for the hyperventilation-induced heart rate 
response (HRRHV) in each group, where beta blocker status is indicated by colour. BB + indicates that beta 
blockers were taken the day of the study, while BB- indicates people who were not prescribed beta blockers at 
the time of the study. Sample size for each is indicated in Table 1.
Figure 4. HRRHV Reproducibility. Initial and secondary measures of hyperventilation-induced heart rate (HRRHV) changes 
in 20 healthy controls. ICC = 0.900, p < 0.001. The red line indicates the line of identity (x = y).
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In the present study, with increasing age, there is a reduction in the HRRHV in healthy controls which can make 
it more difficult to distinguish between groups (Fig. 2). In healthy controls, HRRHV was diminished with age. A 
negative correlation of the stress induced heart rate reserve to age is well established14,26–28. This is in part due 
to the fact that maximal heart rate decreases approximately 4–5% per decade29, thereby reducing the heart rate 
response. Nevertheless, we still observed a significant attenuation in the patients in comparison to age-matched 
controls. While not the primary goal of the study, we also investigated potential diagnostic cut-off values. When 
using HRRHV to separate age-stratified controls from the combined patient group, a lower HRRHV cut-off of 8.5 
yielded a positive predictive value of 89%, while an upper cut-off of 15.5 bpm resulted in a negative predictive 
value of 91%. These proposed cut-off values are preliminary and should be validated with a larger cohort of which 
the prevalence of cardiovascular disease is not pre-defined as it was in our analysis with specific sample sizes per 
group to truly test the role of HRRHV as a discriminatory marker.
Furthermore, gender may play a role in heart rate responses to stimuli. It has been demonstrated that with 
pharmacological agents, women had a different heart rate response than men17. While Alexopolous et al. reported 
that with a prolonged 5-minute period of hyperventilation the heart rate response did not differ between male 
and female healthy controls, but multivariable analysis revealed gender was an independent predictor30. As shown 
in Supplemental Fig. 1, gender was not associated with the heart rate response to hyperventilation for any group, 
however we did not have the sample size to rigorously investigate this variable. Furthermore, there are known 
gender biases associated with some cardiovascular diseases that may influence comparisons between groups. 
For example, studies with CAD populations are often predominantly male31, while females have a higher or at 
least equal representation in studies of HFpEF32. These gender proportions are also reflected in our data. Other 
confounders are present as many common cardiovascular medications can impact the heart rate and its response 
to stress33, in particular beta blockers and non-dihydropyridine calcium channel blockers. Beta blockers did not 
have a significant effect on the HR response, regardless of whether they were taken, withheld, or not prescribed 
at all. In the literature, results on the impact of beta blockers on heart rate measurements are mixed. For example, 
the resting HR and HRRHV in advanced HF was reported higher in patients when beta-blockers were withheld 
during treadmill exercise than when the test was repeated in the same patients 3 hours after beta blocker adminis-
tration34, while other studies have reported that in HF patients, the heart rate response to stress was not associated 
with beta blocker use27. The effects of withholding beta blockers before stress testing has previously been exam-
ined in myocardial imaging, and it was shown that beta blocker withdrawal did not affect the diagnostic sensi-
tivity35. Yet, there is little knowledge about the relationship with beta blockers and hyperventilation. In a larger 
population this impact will have to be assessed further, and different thresholds for patients on beta blockers may 
need to be developed, as this study is limited by power.
In patients with cardiovascular disease, several comorbidities occur with higher prevalence than in a healthy 
population. Frequent comorbidities such as diabetes, obesity, smoking and other cardiovascular risk factors are 
associated with impaired autonomic regulation. Hypertension is correlated with a higher resting HR36, and HR 
variability could hold prognostic power for the development of hypertension36. In diabetic patients, parasympa-
thetic denervation is followed by reduced HR variability, resting tachycardia, and a fixed HR37. Obesity is cor-
related with reduced parasympathetic function and a higher resting HR. Similarly, smoking has been shown 
to be associated with a higher resting HR and a slower reactivity to exercise stimulus38. Cardiovascular disease 
is also closely linked with sleep apnea, with over half of clinically diagnosed sleep apnea patients also having a 
history of cardiovascular disease39. There is also a higher incidence of sleep apnea in HF and CAD patients as 
compared to healthy controls, with potential physiological links through autonomic dysfunction and impaired 
mechanical function40. Additionally, Cheyne-Stokes breathing is common in HF patients41, and recurrent 
hypercapnia and cardiopulmonary interaction can be associated with a highly periodic HR variation42. Each of 
these comorbidities affects the autonomic nervous system, potentially contributing to increased variability in 
hyperventilation-induced heart rate changes in the cardiovascular patient populations. Thus, it may be difficult to 
discern the etiology of hyperventilation-induced HR change between groups as it may reflect the impact of such 
comorbidities rather than cardiovascular disease itself.
In addition to the aforementioned limitations, the categorical classification of our patient groups as CAD, 
HF, CAD+/HF+, CAD−/HF−, or healthy precluded a statistical assessment of disease severity including the 
relationship with symptoms. For CAD patients only binary classification for presence of CAD was consistently 
available from all studies, preventing us from conducting a more complex subgroup analysis according to the 
severity, number and type of stenosed vessels. The limited sample size also required grouping of a variety of 
different disease profiles into the CAD+/HF + group, including those with any combination of current and 
re-perfused CAD. We also present a simple pooled analysis using data only from specified participating sites, 
HRRHV
All Controls Age-Stratified
8.5 15.5 8.5 15.5
Sensitivity 78% (72–84) 91% (85–95) 75% (63–84) 87% (72–94)
Specificity 87% (79–92) 72% (65–79) 86% (73–94) 69% (58–79)
Positive Predictive Value 92% (87–96) 73% (65–79) 89% (78–95) 59% (46–71)
Negative Predictive Value 67% (58–75) 91% (84–95) 70% (58–80) 91% (80–96)
Table 3. Potential HRRHV Diagnostic Cut-offs. The diagnostic potential of a lower hyperventilation-induced 
heart rate (HRRHV) cut-off of 8.5 bpm, and an upper cut-off of 15.5 bpm are shown with 95% confidence 
intervals for the comparison of all cardiovascular patients versus all controls and secondly for the age-stratified 
patients and control comparison.
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and not a meta-analysis. The data is not weighted based on the origin of the study, and subsequently our analysis 
does not account for potential bias between studies and sites. Another limitation of this retrospective analysis was 
each study performed their own technique independently. While each site performed a 60 s period of hyperven-
tilation, the standardization of the protocol between sites was not controlled. Additionally, with no metrics for 
the magnitude of the response in each individual, for example a comparison to advanced imaging measurements 
such as myocardial perfusion or to a known stimulus such as adenosine, we were unable to control or account 
for potential differences in the breathing maneuver. A strict, standardized protocol could be implemented in a 
prospective trial, limiting between-site variation with direct comparisons to known stress techniques. Using a 
different hyperventilation technique, Alexopolous et al. found that the heart rate response was not as strong with 
hyperventilation in comparison to exercise30. In a small group of controls included in this analysis, we previously 
published that the heart rate response to hyperventilation was comparable to that of adenosine43. This comparison 
has not yet been investigated in patients.
Reproducibility analysis is not available for the patient groups, however, the test-retest reliability in 20 healthy 
controls suggests that HRRHV is highly reproducible. Finally, HR was measured from ECG tracings inside a mag-
netic environment that may be subject to artifacts. The overall quality of ECG however was monitored during the 
scan. While the hemodynamic effects of hyperventilation are more extensively studied30,44, future assessments 
could look into the effect, reproducibility and feasibility of other breathing maneuvers such as breath-holding or 
paced breathing protocols.
The present study suggests that a hyperventilation-induced increase in heart rate (HRRHV) is attenuated in 
patients with cardiovascular disease. HRRHV should be further investigated for its potential utility as a simple, 
accessible, and inexpensive pre-screening test with the potential to help improve patient selection for more expen-
sive diagnostic modalities. A prospective study with a tightly protocolized breathing maneuver and a larger sam-
ple size should be conducted to evaluate a more accurate cut-off between healthy and disease populations while 
also assessing any potential adverse effects. The goal of future assessments would be to use more universal HR 
measuring devices that are publicly available including newer wearable devices that report additional variables 
such as heart rate variability.
Methods
Study design. The primary aim of this retrospective pooled analysis was to investigate differences in the 
heart rate responses to a short period of hyperventilation between controls and patients with cardiovascular dis-
ease. Data was collected from studies that were conducted between 2010 and 2018 at the Bern University Hospital 
in Switzerland, the Stephenson Cardiac Imaging Centre, the Montreal Heart Institute, and the McGill University 
Health Centre in Canada19–21,45–47 (NCT03050346, NCT02233634 of original studies). Hemodynamic responses 
to HR was not the defined end-point in any of the original studies. We pooled data from studies at these sites that 
applied the specific 60 s hyperventilation technique in their study in rest conditions, based on the protocol first 
used by Guensch et al.45. Nine studies were included with a total of 282 participants, each of which measured the 
heart rate response to 60 s of hyperventilation in healthy controls, patients with known or suspected CAD, or HF 
patients. Each of the included studies used the same 60 s hyperventilation technique in addition to other breath-
ing maneuvers as part of a cardiac magnetic resonance (MR) imaging protocol.
Hyperventilation procedure. Following a period of normal breathing, resting HR was recorded, after 
which hyperventilation commenced at a pace of at least 30 breaths per minute for 60 seconds. Immediately after, 
the post-hyperventilation heart rate was recorded, and HRRHV was calculated as the relative difference to the 
resting HR. HR was recorded with an MRI-compatible ECG tracer, typically using three to four leads and directly 
recorded onto the images which could then be verified post-exam. Demographic information, along with ven-
tricular function parameters were obtained on the day of the procedure.
participants. In all studies, healthy controls were screened for disorders and medications that are 
known to affect the cardiovascular and respiratory systems. Participants from the studies were combined and 
re-classified into five groups: healthy controls, patients who presented with CAD symptoms but had no signif-
icant coronary stenosis as evaluated via angiography (CAD−/HF− group), angiographically validated CAD 
patients (CAD + group), HF patients (HF + group), and patients with both HF and a history of CAD (CAD+/
HF + group). Patients in the CAD + group had at least one untreated coronary stenosis ≥50% of the diameter 
as evaluated by angiography at the time of the hyperventilation procedure. Patients with heart failure (HF+) 
included patients both with reduced (<50%) and preserved (≥50) ejection fraction, had no known history of 
CAD and were presenting with heart failure symptoms, with either New York Heart Association classification 
of ≥2 or a positive B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NTproBNP). 
CAD+/HF + patients met the HF criteria and had a history of CAD, while patients in the CAD-/HF- group were 
patients without heart failure or a previous history of CAD who had been referred for an invasive angiography at 
the time of the hyperventilation procedure for the suspicion of CAD, with no relevant obstructive stenosis found 
on the resulting exam. Patients with implantable cardioverter defibrillators or pacemakers were excluded. More 
specific inclusion and exclusion criteria can be found in the relevant publications and in the NCT registry.
Each study was approved by the local research boards at the aforementioned sites, the Cantonal Ethics 
Committee of Bern, Bern, Switzerland, the Conjoint Health Research Ethics Board, Alberta, Canada, and the 
Montreal Heart Institute Research Ethics Board and McGill University Health Centre Research Ethics Board, 
Quebec, Canada. Written informed consent was obtained from all subjects. The data included in this specific 
analysis were either published with data available upon request, conducted on participants who gave consent to 
secondary use of their data, or were granted approval for secondary use of data by local research ethics boards. All 
methods were carried out in accordance with relevant guidelines and regulations.
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Data analysis. Statistical analysis and presentation were performed primarily with MATLAB (R2018a with 
the Image Processing Toolbox and the Statistics and Machine Learning Toolbox as well as the plotSpread func-
tion48) and GraphPad Prism (GraphPad Software version 8.0 for Mac OS, La Jolla California USA).
Firstly, the HRRHV was compared to participant demographic variables using correlation analysis for each 
group. To compare the data between the individual groups, a sub-group of healthy controls 55 years and older 
was used as the reference. Demographic characteristics (age, body mass index (BMI), diastolic and systolic blood 
pressure, gender, ejection fraction, cardiac index, resting HR) were compared across groups, using ANOVA for 
continuous variables and a non-parametric ANOVA for categorical variables, with Bonferroni or Dunn’s multiple 
comparison post-hoc analysis for a direct comparison to the healthy control sub-group (≥55 years) if appropriate. 
An ANOVA and post-hoc analysis were then performed for comparing HRRHV between all four disease groups 
and the sub-group of healthy controls (≥55 years). By using this older healthy control sub-group with similar 
demographics to the patient groups (Table 1), no covariates were added to the statistical model.
Receiver operating characteristic (ROC) curves were used to assess preliminary cut-offs between healthy and 
patient groups. Subsequent analysis was performed to assess the diagnostic accuracy of the cut-offs. Prior to this 
assessment, all cardiovascular patient were combined into a single patient group. As age is a significant factor in 
HRRHV, an additional age-stratification selection process was conducted to make two groups with an equal num-
ber of age matched patients following previously reported procedures49. The participants were stratified into three 
age bins (40–49, 50–59, 60–72), with an equal number of patients and controls pseudo-randomized for inclusion 
into each bin. With this sub-analysis population, n = 54 were available for each group.
Finally, reproducibility of HRRHV was also assessed in the 20 healthy controls who completed the breathing 
maneuver multiple times. Test-retest reproducibility was assessed with both the Lin concordance coefficient and 
the absolute single measure intraclass correlation coefficient (ICC) using a two-way mixed model. Unless other-
wise indicated, all stats are reported as mean ± standard deviation.
Data availability
All data generated or analyzed during this study are included in this published article (and its Supplementary 
Information files, Supplementary Dataset 1).
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